IONS combines 87% year-over-year revenue growth, a perfect four-quarter earnings beat streak averaging 131% upside surprise, and a 24.3% runway to the analyst consensus target at a 4.5-to-1 reward/risk ratio — but deeply negative free cash flow at minus 76% of revenue, a weak balance sheet, and price momentum below the long-term moving average create meaningful execution risk that must be monitored closely.
Thesis pillars
- Exceptional Revenue Growth→Stable
- Perfect Earnings Beat Streak→Stable
- Cash Burning Operations→Stable
- +2 more pillars — see the Why tab for full reasoning
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $81.80: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 14%; Below-average business quality.
Ionis Pharmaceuticals develops and commercializes RNA-targeted antisense medicines for serious diseases, with seven marketed products including TRYNGOLZA and DAWNZERA independently commercialized in the US and SPINRAZA and QALSODY partnered with Biogen. The company reported $944... Read more
Sell if holding. Engine safety override at $81.80: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 14%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Ionis Pharmaceuticals, Inc.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals reported $944 million in 2025 revenue with seven marketed RNA-targeted antisense medicines spanning SMA, ALS, ATTRv-PN, HAE, and FCS. Two independent U.S. launches are underway—TRYNGOLZA (FDA-approved December 2024 for familial chylomicronemia syndrome) and DAWNZERA (FDA-approved August 2025 for hereditary angioedema)—while SPINRAZA, commercialized by partner Biogen worldwide, is the global market leader for spinal muscular atrophy. The company held $2.7 billion in cash and short-term investments at December 31, 2025.
Ionis earns revenue through product sales from independently commercialized U.S. medicines, royalties and milestones from Biogen (for SPINRAZA and QALSODY commercialized worldwide) and AstraZeneca (WAINUA co-commercialized in the U.S., with AstraZeneca holding exclusive rest-of-world rights), and distribution arrangements for TEGSEDI and WAYLIVRA through Sobi in Europe and PTC Therapeutics in Latin America. The majority of U.S. target patients rely on Medicare, Medicaid, managed care, and private insurance for coverage; pricing is subject to the IRA's Medicare Drug Price Negotiation Program, which selects up to 20 single-source drugs per year and could materially reduce per-unit reimbursement for selected products. Third-party manufacturers supply drug substance and drug product for TRYNGOLZA, DAWNZERA, and WAINUA, with many suppliers located outside the United States, exposing the company to tariff-related cost increases. The wholly owned late-stage pipeline includes obudanersen in Phase 3 for Angelman syndrome (advanced Q2 2025), zilganersen with NDA submitted in January 2026 for Alexander disease, and olezarsen under priority FDA review for severe hypertriglyceridemia with a PDUFA date of June 30, 2026.
Show full overview
Biogen's role as sole global commercializer of both SPINRAZA and QALSODY represents a concentrated counterparty dependency. The 10-K states Ionis cannot control the amount and timing of resources Biogen devotes to either collaboration, and Biogen may terminate the arrangements at any time without cause. SPINRAZA revenue has already declined in past periods due to competition from a gene therapy and an oral SMA product, and the 10-K acknowledges future sales "may be adversely affected by competing products." Should Biogen exit either collaboration, Ionis would need to redirect capital and management resources—a meaningful execution risk given two simultaneous independent launches already underway.
See also: Healthcare · Biotechnology
From Ionis Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Ionis Pharmaceuticals, Inc.
Latest news
- NEWS Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75 — benzinga Jun 25, 2026 positive
- NEWS Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk — benzinga Jun 25, 2026 positive
- NEWS Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129 — benzinga Jun 25, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $130 — benzinga Jun 25, 2026 positive
- NEWS Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Disease In All Countries O — benzinga Jun 25, 2026 positive
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMcounterpartyBiogen10-K Item 1A: 'We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.'
- MEDIUMcounterpartyAstraZeneca10-K Item 1A: 'We depend on our collaboration with AstraZeneca for the joint development and commercialization of WAINUA.'
Material Events(8-K, last 90d)
- 2026-06-08Item 5.02LOWLudwig N. Hantson appointed to Ionis Board of Directors effective June 4, 2026, following 2026 Annual Meeting. Hantson is former CEO of Alexion (2017-2021). Routine non-employee director appointment; no arrangements with other persons cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $81.80: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 14%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $77.06. Score 5.3/10, moderate confidence.
Take-profit target: $95.32 (+16.5% upside). Prior stop was $77.06. Stop-loss: $77.06.
Quality below floor (1.8 < 4.0).
Ionis Pharmaceuticals, Inc. trades at a P/E of N/A (forward -134.4). TrendMatrix value score: 5.1/10. Verdict: Sell.
33 analysts cover IONS with a consensus score of 4.1/5. Average price target: $106.
What does Ionis Pharmaceuticals, Inc. do?Ionis Pharmaceuticals develops and commercializes RNA-targeted antisense medicines for serious diseases, with seven...
Ionis Pharmaceuticals develops and commercializes RNA-targeted antisense medicines for serious diseases, with seven marketed products including TRYNGOLZA and DAWNZERA independently commercialized in the US and SPINRAZA and QALSODY partnered with Biogen. The company reported $944 million in 2025 revenues and held $2.7 billion in cash and short-term investments at year-end.